Lung Cancer Non-Small Cell Cancer (NSCLC) Recruiting Phase 1 / 2 Trials for Docetaxel (DB01248)

Also known as: Non - Small Cell Lung Cancer NSCLC / Carcinoma, Non-Small-Cell Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma / Nonsmall Cell Lung Cancer / Lung Cancer(NSCLC) / Non-Small Cell Lung Cancer / Non-Small-Cell Lung Cancer (NSCLC) / NSCLC (Non-Small Cell Lung Cancer) / Non Small Cell Lung Cancer (NSCLC) / Lung Cancer (Non-Small Cell) / NSCLC, Non Small Cell Lung Cancer / Non-small Cell Lung Cancers / Lung Cancer, Nonsmall Cell / Non-Small Cell Lung Carcinoma / Lung Cancer Non-Small Cell / Non-Small-Cell Lung Cancer / Non-Small Cell Lung Cancer (NSCLC) / Non Small Cell Lung Cancer / Non-Small Cell Lung Carcinoma (NSCLC) / Carcinoma, Non-Small Cell Lung / Lung Cancer, Non-Small Cell / Non Small-cell Lung Cancer / NSCLC Non-small Cell Lung Cancer / NSCLC / Non Small Cells Lung Cancer / Non-Small Cell Lung Cancer(NSCLC) / Non- Small Cell Lung Cancer / Lung Cancer - Non Small Cell / Lung Cancer (NSCLC) / Non Small Cell Lung Cancer NSCLC / Non-Small-Cell-Lung Cancer (NSCLC) / Non-Small-Cell-Lung Cancer / Non-small cell lung cancer (disorder) / Non-small cell lung cancer NOS

IndicationStatusPhase
DBCOND0046916 (Lung Cancer Non-Small Cell Cancer (NSCLC))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04165031A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C MutationTreatment
NCT03726736Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLCTreatment
NCT03095612Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)Treatment
NCT02884479An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation StudyTreatment
NCT03840915M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)Treatment
NCT03337698A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)Treatment
NCT02450656Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerTreatment
NCT02393248Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)Treatment